Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial

The Lancet

Volumn 390, Issue 10108, 2017, Pages 2160-2170

  Townsend, Raymond R ^a   Mahfoud, Felix ^b,c   Kandzari, David E ^d   Kario, Kazuomi ^e   Pocock, Stuart ^f   Weber, Michael A ^g   Ewen, Sebastian ^b   Tsioufis, Konstantinos ^h   Tousoulis, Dimitrios ^h   Sharp, Andrew S P ⁱ   Watkinson, Anthony F ⁱ   Schmieder, Roland E ^j   Schmid, Axel ^j   Choi, James W ^k   East, Cara ^k,t   Walton, Anthony ^l   Hopper, Ingrid ^m   Cohen, Debbie L ^a,r   Wilensky, Robert ^a   Lee, David P ⁿ   Ma, Adrian ^n,t   Devireddy, Chandan M ^o   Lea, Janice P ^o   Lurz, Philipp C ^p   Fengler, Karl ^p   Davies, Justin ^q   Chapman, Neil ^q   Cohen, Sidney A ^a,r   DeBruin, Vanessa ^r   Fahy, Martin ^r   Jones, Denise E ^r   Rothman, Martin ^r,s   Böhm, Michael ^b,t   Aoki, Jiro ^t   Batson, Bryan ^t   Dangas, George ^t   David, Shukri ^t   Patel, Manesh ^t   Patel, Kiritkumar ^t   Singh, Jasvindar ^t   Weber, Thomas ^t   Weil, Joachim ^t   Zeller, Thomas ^t   Ziada, Khaled ^t   Tanabe, Kengo ^t   Wilkins, Robert ^t   Contreras, Johanna ^t   Steigerwalt, Susan ^t   Reedus, Denise ^t   Hoshide, Satoshi ^t   Svetkey, Laura ^t   Rao, Anjani ^t   Brown, Angela ^t   Suppan, Markus ^t   Agdirlioglu, Tolga ^t   Noory, Elias ^t   Chasen, Craig ^t   more..

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b SAARLAND UNIVERSITY   (Germany)

^c Massachusetts Institute of Technology   (United States)

^d PIEDMONT HEART INSTITUTE   (United States)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^g Downstate Health Sciences University   (United States)

^h UNIVERSITY OF ATHENS   (Greece)

ⁱ ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^j UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^k BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^l MONASH UNIVERSITY   (Australia)

^m ALFRED HOSPITAL   (Australia)

ⁿ STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^o EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p UNIVERSITY OF LEIPZIG   (Germany)

^q HAMMERSMITH HOSPITAL   (United Kingdom)

^r MEDTRONIC INC   (United States)

^s BARTS HEALTH NHS TRUST   (United Kingdom)

^t NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ARTICLE; AUSTRALIA; AUSTRIA; CAREGIVER; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EUROPE; FEMALE; FOLLOW UP; GERMANY; GREECE; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; JAPAN; KIDNEY ANGIOGRAPHY; KIDNEY DENERVATION; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SYSTOLIC BLOOD PRESSURE; THERAPY EFFECT; UNITED KINGDOM; UNITED STATES; AGE; AGED; BLOOD PRESSURE MEASUREMENT; CATHETER ABLATION; CLINICAL TRIAL; DRUG RESISTANCE; INTERNATIONAL COOPERATION; PROCEDURES; PROGNOSIS; REFERENCE VALUE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTOR; SYMPATHECTOMY; TREATMENT OUTCOME;

ADULT; AGE FACTORS; AGED; ANTIHYPERTENSIVE AGENTS; AUSTRALIA; BLOOD PRESSURE DETERMINATION; CATHETER ABLATION; DRUG RESISTANCE; EUROPE; FEMALE; HUMANS; HYPERTENSION; INTERNATIONALITY; MALE; MIDDLE AGED; PATIENT SAFETY; PROGNOSIS; REFERENCE VALUES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SINGLE-BLIND METHOD; SYMPATHECTOMY; TREATMENT OUTCOME; UNITED STATES;

EID: 85028396109     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32281-X     Document Type: Article

References (36)

1. Esler, M, Jennings, G, Korner, P, et al. Assessment of human sympathetic nervous system activity from measurements of norepinephrine turnover. Hypertension 11 (1998), 3–20.
2. Symplicity, HTNI, Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 57 (2011), 911–917.
3. Symplicity, HTNI, Esler, MD, Krum, H, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 376 (2010), 1903–1909.
4. Bhatt, DL, Kandzari, DE, O'Neill, WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 370 (2014), 1393–1401.
5. Kandzari, DE, Bhatt, DL, Brar, S, et al. Predictors of blood pressure response in the SYMPLICITY HTN-3 trial. Eur Heart J 36 (2015), 219–227.
6. Kandzari, DE, Kario, K, Mahfoud, F, et al. The SPYRAL HTN Global Clinical Trial Program: Rationale and design for studies of renal denervation in the absence (SPYRAL HTN OFF-MED) and presence (SPYRAL HTN ON-MED) of antihypertensive medications. Am Heart J 171 (2016), 82–91.
7. Helfer, AG, Michely, JA, Weber, AA, Meyer, MR, Maurer, HH, Orbitrap technology for comprehensive metabolite-based liquid chromatographic-high resolution-tandem mass spectrometric urine drug screening—exemplified for cardiovascular drugs. Anal Chim Acta 891 (2015), 221–233.
8. Shimamoto, K, Ando, K, Fujita, T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 37 (2014), 253–390.
9. White, WB, Turner, JR, Sica, DA, et al. ASH Scientific Statement: detection, evaluation and treatment of severe and resistant hypertension. Proceedings from an American Society of Hypertension Interactive Forum; Bethesda, MD, USA; Oct 10, 2013. J Am Soc Hypertens 8 (2014), 743–757.
10. James, KE, Bloch, DA, Lee, KK, Kraemer, HC, Fuller, RK, An index for assessing blindness in a multi-centre clinical trial: disulfiram for alcohol cessation—a VA cooperative study. Stat Med 15 (1996), 1421–1434.
11. Krum, H, Schlaich, M, Whitbourn, R, et al. Catheter-based renal sympathetic denervation for resistanthypertension: a multicentre safety and proof-of-principle cohort study. Lancet 373 (2009), 1275–1281.
12. Mompeo, B, Maranillo, E, Garcia-Touchard, A, Larkin, T, Sanudo, J, The gross anatomy of the renal sympathetic nerves revisited. Clinical Anatomy 29 (2016), 660–664.
13. Ott, C, Mahfoud, F, Schmid, A, et al. The effect of renal denervation in moderate treatment-resistant hypertension with confirmed medication adherence. J Hypertens 34 (2016), 2475–2479.
14. Mahfoud, F, Tunev, S, Ewen, S, et al. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation. J Am Coll Cardiol 66 (2015), 1766–1775.
15. Mahfoud, F, Bakris, G, Bhatt, DL, et al. Reduced blood pressure-lowering effect of catheter-based renal denervation in patients with isolated systolic hypertension: data from SYMPLICITY HTN-3 and the Global SYMPLICITY Registry. Eur Heart J 38 (2017), 93–100.
16. Kaltenbach, B, Franke, J, Bertog, SC, Steinberg, DH, Hofmann, I, Sievert, H, Renal sympathetic denervation as second-line therapy in mild resistant hypertension: a pilot study. Catheter Cardiovasc Interv 81 (2013), 335–339.
17. Brinker, S, Pandey, A, Ayers, C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol 63 (2014), 834–835.
18. Jung, O, Gechter, JL, Wunder, C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens 31 (2013), 766–774.
19. Azizi, M, Pereira, H, Hamdidouche, I, et al. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal denervation in the renal denervation for hypertension (DENERHTN) Trial. Circulation 134 (2016), 847–857.
20. de Jager, RL, de Beus, E, Beeftink, MM, et al. Impact of medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension 69 (2017), 678–684.
21. Ewen, S, Meyer, MR, Cremers, B, et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol 104 (2015), 1097–1105.
22. Linicus, Y, Kindermann, I, Helfer, AG, et al. Witnessed drug intake before planned denervation—always harmless?. Int J Cardiol 179 (2015), 125–126.
23. Tomaszewski, M, White, C, Patel, P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 100 (2014), 855–861.
24. Azizi, M, Sapoval, M, Gosse, P, et al. Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multicentre, open-label, randomised controlled trial. Lancet 385 (2015), 1957–1965.
25. De Jager, RL, Sanders, MF, Bots, ML, et al. Renal denervation in hypertensive patients not on blood pressure lowering drugs. Clin Res Cardiol 105 (2016), 755–762.
26. Fadl Emula, FE, Feng, YM, Jacobs, L, et al. Sham or no sham control: that is the question in trials of renal denervation for resistant hypertension. A systematic meta-analysis. Blood Press 26 (2017), 195–203.
27. Mahfoud, F, Schmieder, RE, Azizi, M, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J, 2017 published online May 5. DOI:10.1093/eurheartj/ehx215.
28. Weber, MA, Kirtane, A, Mauri, L, Townsend, RR, Kandzari, DE, Leon, MB, Renal denervation for the treatment of hypertension: making a new start, getting it right. J Clin Hypertens 17 (2015), 743–750.
29. Mahfoud, F, Bohm, M, Azizi, M, et al. Proceedings from the European clinical consensus conference for renal denervation: considerations on future clinical trial design. Eur Heart J 36 (2015), 2219–2227.
30. Howard, JP, Cole, GD, Sievert, H, et al. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. Int J Cardiol 172 (2014), 29–35.
31. Zannad, F, Stough, WG, Mahfoud, F, et al. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension 65 (2015), 5–15.
32. Bundy, JD, Li, C, Stuchlik, P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol 2 (2017), 775–781.
33. Ettehad, D, Emdin, CA, Kiran, A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387 (2016), 957–967.
34. Kario, K, Pickering, TG, Umeda, Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 107 (2003), 1401–1406.
35. Dolan, E, Stanton, A, Thijs, L, et al. Superiority of ambulatory over clinic blood pressure measurement in predicting mortality: the Dublin outcome study. Hypertension 46 (2005), 156–161.
36. Mancia, G, Facchetti, R, Bombelli, M, Grassi, G, Sega, R, Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 47 (2006), 846–853.